Phase I Study of the Aurora Kinase A Inhibitor MLN8237 in Combination With the Histone Deacetylase Inhibitor Vorinostat in Lymphoid Malignancies.

Trial Profile

Phase I Study of the Aurora Kinase A Inhibitor MLN8237 in Combination With the Histone Deacetylase Inhibitor Vorinostat in Lymphoid Malignancies.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Alisertib (Primary) ; Vorinostat
  • Indications B cell lymphoma; Hodgkin's disease; Peripheral T-cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 17 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
    • 08 Dec 2015 Results (n=25) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 04 Dec 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top